Publications by authors named "Buehning F"
Immune checkpoint inhibitor (ICI) therapy represents a ground-breaking paradigm in cancer treatment, harnessing the immune system to combat malignancies by targeting checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). The use of ICI therapy generates distinctive immune-related adverse events (irAEs) including cardiovascular toxicity, necessitating targeted research efforts. This comprehensive review explores preclinical models dedicated to ICI-mediated cardiovascular complications including myocarditis.
View Article and Find Full Text PDFArticle Synopsis
- Cardiac amyloidosis (CA) is a serious condition caused by proteins misfolding and accumulating in the heart, primarily involving two types: Transthyretin amyloid (ATTR) and immunoglobulin light chain amyloid.
- There are over 100 clinical trials currently underway aimed at developing better therapies for CA, as existing heart failure treatments can be ineffective and hard to tolerate due to this condition.
- Tafamidis, the first approved treatment for ATTR, is seeing increased usage, while new potential therapies like silencers, antibodies, and genetic treatments are in advanced trial stages, highlighting the urgent need for effective CA management in heart failure care.